

Web-only references

1. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, *et al.* Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. *J Am Coll Cardiol* 1992 Nov 1;**20**(5):1056–62.
2. Singh SN, Fletcher RD, Fisher SG, *et al.* Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. *N Engl J Med* 1995 Jul 13;**333**(2):77–82.
3. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. *Am Heart J* 1959 Jul;**58**(1):59–70.
4. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. *Am Heart J* 1989 Jan;**117**(1):151–9.
5. Josephson ME, Spielman SR, Greenspan AM, *et al.* Mechanism of ventricular fibrillation in man. *Am J Cardiol* 1979 Oct;**44**(4):623–31.
6. Zipes DP. Electrophysiological mechanisms involved in ventricular fibrillation. *Circulation* 1975 Dec;**52**(Suppl 6):III120–30.
7. Qin D, Zhang ZH, Caref EB, Boutjdir M, Jain P, el-Sherif N. Cellular and ionic basis of arrhythmias in postinfarction remodeled ventricular myocardium. *Circ Res* 1996 Sep;**79**(3):461–73.
8. Pogwizd SM, Corr PB. Reentrant and nonreentrant mechanisms contribute to arrhythmogenesis during early myocardial ischemia: results using three-dimensional mapping. *Circ Res* 1987 Sep;**61**(3):352–71.
9. Li GR, Lau CP, Ducharme A, *et al.* Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. *Am J Physiol Heart Circ Physiol* 2002 Sep;**283**(3):H1031–41.
10. Laurita KR, Katra R, Wible B, *et al.* Transmural heterogeneity of calcium handling in canine. *Circ Res* 2003 Apr 4;**92**(6):668–75.
11. O'Rourke B, Kass DA, Tomaselli GF, *et al.* Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. *Circ Res* 1999 Mar 19;**84**(5):562–70.
12. Janse MJ, Vermeulen JT, Opthof T, *et al.* Arrhythmogenesis in heart failure. *J Cardiovasc Electrophysiol* 2001 Apr;**12**(4):496–9.
13. Gómez AM, Valdivia HH, Cheng H, *et al.* Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. *Science* 1997 May 2;**276**(5313):800–6.
14. Pogwizd SM, Qi M, Yuan W, *et al.* Upregulation of Na(+)/Ca(2+) exchanger expression and function in an arrhythmogenic rabbit model of heart failure. *Circ Res* 1999 Nov 26;**85**(11):1009–19.
15. Mercadier JJ, Lompre AM, Duc P, *et al.* Altered sarcoplasmic reticulum Ca²⁺-ATPase gene expression in the human ventricle during end-stage heart failure. *J Clin Invest* 1990 Jan;**85**(1):305–9.
16. Weiss JN, Chen PS, Qu Z, *et al.* Ventricular fibrillation: how do we stop the waves from breaking? *Circ Res* 2000 Dec 8;**87**(12):1103–7.

17. Weiss JN, Chen PS, Qu Z, *et al.* Review. Electrical restitution and cardiac fibrillation. *J Cardiovasc Electrophysiol* 2002 Mar;**13**(3):292–5.
18. Pastore JM, Girouard SD, Laurita KR, *et al.* Mechanism Linking T-Wave Alternans to the Genesis of Cardiac Fibrillation. *Circulation* 1999 Mar 16;**99**(10):1385–94.
19. Pastore JM, Rosenbaum DS. Role of Structural Barriers in the Mechanism of Alternans-Induced Reentry. *Circ Res* 2000 Dec 8;**87**(12):1157–63.
20. Wilber DJ, Olshansky B, Moran JF, *et al.* Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. *Circulation* 1990 Aug;**82**(2):350–8.
21. Bailey JJ, Berson AS, Handelsman H, *et al.* Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. *J Am Coll Cardiol* 2001 Dec;**38**(7):1902–11.
22. La Rovere MT, Bigger JT Jr, Marcus FI, *et al.* Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet* 1998 Feb 14;**351**(9101):478–84.
23. La Rovere MT, Pinna GD, Hohnloser SH, *et al.* Autonomic Tone and Reflexes After Myocardial Infarction. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. *Circulation* 2001 Apr 24;**103**(16):2072–7.
24. Buxton AE, Lee KL, DiCarlo L, *et al.* Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med* 2000 Jun 29;**342**(26):1937–45.
25. Gold MR, Bloomfield DM, Anderson KP, *et al.* A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. *J Am Coll Cardiol* 2000 Dec;**36**(7):2247–53.
26. Qu Z, Garfinkel A, Chen PS, *et al.* Mechanisms of discordant alternans and induction of reentry in simulated cardiac tissue. *Circulation* 2000 Oct 3;**102**(14):1664–70.
27. Pastore JM, Girouard SD, Laurita KR, *et al.* Mechanism linking T-wave alternans to the genesis of cardiac fibrillation. *Circulation* 1999 Mar 16;**99**(10):1385–94.
28. Kon-No Y, Watanabe J, Koseki Y, *et al.* Microvolt T wave alternans in human cardiac hypertrophy: electrical instability and abnormal myocardial arrangement. *J Cardiovasc Electrophysiol* 2001 Jul;**12**(7):759–63.
29. Greenberg HM, Dwyer EM Jr, Hochman JS, *et al.* Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. *Br Heart J* 1995 Dec;**74**(6):631–5.
30. Anderson JL, Platia EV, Hallstrom A, *et al.* Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). *Circulation* 1994 Dec;**90**(6):2843–52.
31. Hallstrom AP, Anderson JL, Carlson M, *et al.* Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. *Am Heart J* 1995 Jul;**130**(1):71–9.

32. Anderson JL, Platia EV, Hallstrom A, *et al.* Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). *Circulation* 1994 Dec;**90**(6):2843–52.
33. Akar FG, Rosenbaum DS. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. *Circ Res* 2003 Oct 3;**93**(7):638–45.
34. Shimizu W, Antzelevitch C. Cellular and ionic basis for T-wave alternans under long-QT conditions. *Circulation* 1999 Mar 23;**99**(11):1499–507.
35. Winters SL, Packer DL, Marchlinski FE, *et al.* Consensus statement on indications, guidelines for use, and recommendations for follow-up of implantable cardioverter defibrillators. North American Society of Electrophysiology and Pacing. *Pacing Clin Electrophysiol* 2001 Feb;**24**(2):262–9.
36. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. *Circulation* 1992 Jan;**85**(Suppl 1):I77–91.
37. Antzelevitch C, Shimizu W, Yan GX, *et al.* The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. *J Cardiovasc Electrophysiol* 1999 Aug;**10**(8):1124–52.
38. Marchioli R, Barzi F, Bomba E, *et al.* Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* 2002;**105**:1897–1903
39. Freemantle N, Cleland J, Young P, *et al.* beta Blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ* 1999 Jun 26;**318**(7200):1730–7.
40. Cleland JG, Erhardt L, Murray G, *et al.* Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. *Eur Heart J* 1997 Jan;**18**(1):41–51.
41. Kober L, Torp-Pedersen C, Carlsen JE, *et al.* A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med* 1995 Dec 21;**333**(25):1670–6.
42. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med* 1998 Aug 20;**339**(8):489–97.
43. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. *Lancet* 2001 May 5;**357**(9266):1385–90.
44. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999 Jun 12;**353**(9169):2001–7.
45. Lechat P, Brunhuber K, Hofmann R, *et al.* The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. *Lancet* 1999 Jan 2;**353**(9146):9–13.
46. Pitt D. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). *Eur Heart J* 1995 Dec;**16**(Suppl N):107–10.

